Clinical Trial Update: Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Sonrotoclax in combination with Zanubrutinib and Rituximab for previously untreated Follicular Lymphoma, with recruitment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Sonrotoclax
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Follicular Lymphoma (FL) | Phase 2 | Status: NOT_YET_RECRUITING